p73{alpha} isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expre
June 29th, 2008 | by admin |p73{alpha} isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells.
MYCN activation, mainly by gene amplification, is one of the most frequent molecular events in neuroblastoma (NB) oncogenesis, and is associated with increased malignancy and decreased neuronal differentiation propensity. The frequency of concomitant loss of heterozygosity at the 1p36.3 locus, which harbours the p53 anti-oncogene homologue TP73, indicates that MYCN and p73 alterations may cooperate in the pathogenesis of NB. We have previously shown that p73 isoforms are deregulated in NB tumours and that TAp73 co-operates synergistically with p53 for apoptosis of NB cells, whereas DeltaNp73 activates the expression of neuronal differentiation genes such as BTG2. Herein, using both ectopic expression and RNA interference-mediated silencing of p73 in MYCN amplified NB cells, we show that p73alpha isoforms inhibit MYCN expression at both transcript and protein levels, in spite of transactivator effects on MYCN promoter. To explain this paradox, we found that TAp73alpha exerts negative post-transcriptional effects leading to reduced MYCN mRNA stability. RNA immunoprecipitation experiments suggest that this dominant inhibitory post-transcriptional effect could be due to an interaction between the p73 protein and MYCN mRNA, a hypothesis also raised for the regulation of certain genes by the p53 protein.
Horvilleur E, Bauer M, Goldschneider D, Mergui X, de La Motte A, Bénard J, Douc-Rasy S, Cappellen D.
Interactions Molécularies et Cancer, Unité Mixte de Recherche 8126 - Centre National de Recherche Scientifique-Université Paris Sud-11 - Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France, Apoptose, Cancer et Développement,Unité Mixte de Recherche 5238, Centre National de Recherche Scientifique - Université de Lyon, Centre Léon Bérard, 69008 Lyon and Département de Biologie et Pathologie Médicales, Institut de Cancérologie Gustave Roussy, 94805 Villejuif, France.